• No results found

Inhibition of Latent Membrane Protein 1 Impairs the Growth and Tumorigenesis of Latency II Epstein-Barr Virus-Transformed T Cells

N/A
N/A
Protected

Academic year: 2019

Share "Inhibition of Latent Membrane Protein 1 Impairs the Growth and Tumorigenesis of Latency II Epstein-Barr Virus-Transformed T Cells"

Copied!
10
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

FIG 1 Expression of LMP1 dominant negative forms in latency II EBV-transformed T cells
FIG 2 The LMP1-DNs LMP1-TES1S and LMP1-TES2S display an antiprolif-erative effect on latency II EBV-transformed T-cell lines (NC5)
FIG 3 Induction of LMP1-DNs triggers an apoptosis cascade and inhibits survival pathways
FIG 4 LMP1-DNs impair NF-phorylated JNK, JNK, andN-terminal kinase (JNK) signaling pathway in EBV-transformed lymphocyte(NC5) lines
+3

References

Related documents

any one test positive was more sensitive and less specific than the combination of both tests and Anti CCP test alone and more sensitive. but equally specific when

A. Specificity of HCMV binding to the 34- and 32-kDa receptor proteins. Cold competition analyses were performed to demonstrate the specificity of binding of HCMV to the 34- and

We have analyzed LCMV isolates derived from purified CD4+ T cells and macrophages of congenitally infected carrier mice and shown that three types of variants are present in

Infection of baby hamster kidney cells with vesicular stomatitis virus (VSV) results in the accumulation of immature Ul and U2 small nuclear ribonucleoproteins (snRNPs) that

I here declare that this dissertation entitled “ “COMPARITIVE STUDY BETWEEN EFFICACY OF ORAL MISOPROSTOL & VAGINAL MISOPROSTOL & FOLEY BULB WITH OXYTOCIN

Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glyco- proteins: RSV fusion protein can mediate infection and cell fusion. Recombinant

(A) BALB/c/SCID mice were challenged with the indicated doses of wild-type Lister (WT-L), defective Lister (dVV-L), recombinant de- fective Lister expressing p53 (dVV-L-p53),

The aim of the current project was to examine organisational and individual factors considered likely to impact on medication administration performance in the hospital